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response of stable disease, and one patient (3 %) achieved a 
confirmed partial response.
Conclusion Overall, aUY922 exhibited acceptable tox-
icities and demonstrated potential clinical activity in Japa-
nese patients, with similar safety and pharmacokinetic pro-
files to those reported in a preceding global Phase I study in 
Western patients (CaUY922a2101).
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Introduction
Heat-shock proteins (HSPs) are molecular chaperones that 
assist in the structural formation, folding and activation 
of a wide variety of oncogenic client proteins involved in 
diverse cellular processes such as apoptosis, proliferation, 
signal transduction and transcription control [1–4]. These 
client proteins include human epidermal growth factor 
receptor 2 (Her2), estrogen receptor, epidermal growth 
factor receptor, platelet-derived growth factor receptor, vas-
cular endothelial growth factor, aKT, c-KIT and c-MeT 
[1, 2]. HSP90 is the most abundant molecular chaperone 
and is essential for cell survival, proliferation and apopto-
sis. These processes are significantly affected by HSP90 
inhibition, and therefore, HSP90 inhibitors are considered 
to have a strong therapeutic potential in a wide variety of 
tumor types [5]. Indeed, HSP90 inhibitors degrade a vari-
ety of oncogenic client proteins [6–8]. In addition, HSP90 
inhibitors show synergy with various chemotherapeutic 
agents in murine tumor models and sensitize tumor cells to 




Purpose aUY922 is a potent non-geldanamycin inhibi-
tor of heat-shock protein 90. This study was carried out in 
Japanese patients to determine the maximum tolerated dose 
(MTD), and to characterize safety, tolerability and pharma-
cokinetics of single-agent aUY922.
Methods Japanese patients with advanced solid tumors 
whose disease had progressed on at least one line of stand-
ard therapy, or for whom no standard therapy existed, were 
treated with aUY922 (intravenous, once-weekly, 28-day 
cycle, starting dose 8 mg/m2).
Results Thirty-one patients were treated. Two DlTs were 
reported in one patient of the 54 mg/m2 cohort; fatigue 
and decreased appetite (both Grade 3, resolving to Grade 
1 within 8 days). no MTD was determined, and the dose 
recommended for Phase II studies was determined to be 
70 mg/m2 once-weekly. Most common drug-related tox-
icities were diarrhea, night blindness and nausea. Grade 1 
and 2 visual toxicities at high aUY922 doses  ≥22 mg/m2 
were observed. Ten patients (32 %) achieved a best overall 
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is a highly potent, isoxazole-based, non-geldanamycin 
HSP90 inhibitor that inhibits the aTPase activity of HSP90, 
and leads to misfolding of client proteins [9, 10]. aUY922 
has significant antitumor activity in a wide range of cancer 
cell lines and inhibits tumor growth in murine xenograft 
models [9–13]. In a preceding global Phase I study in West-
ern patients (CaUY922a2101), the recommended Phase 
II dose (rP2D) of aUY922 was determined to be 70 mg/
m2 intravenous (IV) once-weekly [14]. Phase II studies 
have been initiated in patients with Her2-positive breast 
cancer, gastric cancer and non-small cell lung cancer to 
further investigate the safety profile and clinical efficacy of 
aUY922 as a single agent and in combination with other 
agents. In these global Phase II studies, aUY922 was well 
tolerated with promising clinical activity as single-agent 
therapy, as well as in combination with other agents, in 
some sub-populations with actively progressing disease 
[15, 16].
In the present open-label, Phase I dose-escalation 
study, the safety, pharmacokinetics (PK) and clinical effi-
cacy of aUY922 were evaluated in Japanese patients with 
advanced solid tumors. The primary objective was to deter-
mine the maximum tolerated dose (MTD) of aUY922 as 
a single agent when administered intravenously on a once-
weekly schedule. Secondary objectives were to character-
ize the safety and tolerability of aUY922 treatment, evalu-
ate the preliminary antitumor activity of aUY922 as a 




adult patients (aged ≥20 years) with histologically con-
firmed, advanced solid tumors whose disease had pro-
gressed on at least one line of standard systemic therapy, or 
for whom no standard therapy existed, were eligible. Inclu-
sion criteria included eastern Cooperative Oncology Group 
performance status ≤2 and life expectancy ≥12 weeks. 
laboratory parameters required were absolute neutro-
phil count ≥1.5 × 109/l, hemoglobin ≥8.5 g/dl, platelets 
≥100 × 109/l, potassium, calcium, magnesium, phospho-
rus within normal limits or correctable with supplements, 
aspartate aminotransferase and alanine aminotransferase 
≤2.5 × upper limit of normal (Uln), serum bilirubin 
≤1.5 × Uln, serum albumin >2.5 g/dl, and serum creati-
nine ≤1.5 × Uln or 24-hour clearance ≥50 ml/min.
exclusion criteria included central nervous system 
metastases, acute or chronic liver or renal disease and pre-
vious treatment with histone deacetylase or HSP90 inhibi-
tors. Patients were excluded who had clinically significant 
heart disease, QTc ≥450 ms on screening electrocardio-
gram (eCG), ischemic heart disease, heart failure, eCG 
abnormalities, atrial fibrillation, atrial flutter or ventricular 
arrhythmias including ventricular tachycardia or Torsades 
de Pointes, or a history (or family history) of long QT syn-
drome. Patients receiving any medication that had a risk 
of prolonging the QTcF interval or inducing Torsades de 
Pointes, and those with disorders known to be caused by a 
deficiency in bilirubin glucuronidation (e.g., Gilbert’s syn-
drome), were also excluded.
This trial was conducted in accordance with the Declara-
tion of Helsinki and the Good Clinical Practice guidelines 
(Japanese Ministry of Health, labour and Welfare). all 
studies were performed after approval by local ethical com-
mittee/institutional review board. Written informed consent 
was obtained from all patients before screening.
Dosing and administration
aUY922 was administered by IV infusion over 1 h, once 
every week (Days 1, 8, 15 and 22) until disease progres-
sion, unacceptable toxicity, or withdrawal by investigator 
decision or patient refusal. The starting dose was 8 mg/
m2, and treatment cycles were 28 days. Intra-patient dose 
escalation was not permitted. an adaptive Bayesian logistic 
regression model (BlrM), guided by the escalation with 
overdose control (eWOC) principle, was used to guide 
dose escalations [17]. The eWOC principle mandates the 
potential doses recommended for the next cohort and the 
estimated MTD have less than 25 % posterior probability 
of DlT in the excessive toxicity interval (33, 100 %). The 
information about dose-limiting toxicity (DlT) available 
from the CaUY922a2101 study at the time of the start 
of this study supported a starting dose of 8 mg/m2 [50 % 
of the highest dose (16 mg/m2) associated with no DlTs]. 
Toxicities at both the 8 and 16 mg/m2 dose levels in that 
study had been mild, and the preliminary PK results had 
shown no accumulation of the drug up to a dose of 16 mg/
m2. The occurrence of DlTs was evaluated during Cycle 
1. a minimum of three patients were enrolled in a cohort, 
and the estimated MTD was continuously updated using 
the BlrM, and a minimum of six patients were planned 
to be enrolled at the MTD level. The final recommended 
dose was based on overall safety assessments and MTD 
estimated by the BlrM, which was the dose of aUY922 
with the highest posterior probability of DlT in the target 
interval (16, 33 %) among the doses fulfilling the eWOC 
principle [18]. a minimum of 15 patients were required 
for the BlrM model to determine the MTD. aUY922 was 
supplied as 10-ml ampoules of a 5-mg/ml solution, which 
was diluted into 5 % dextrose or glucose to a maximum 
infusion volume of 500 ml, under aseptic conditions and 
protected from light to prevent the photolabile drug from 
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decomposition. Doses were individually adjusted according 
to body surface area measured at baseline.
Safety assessments
Toxicity was graded according to the national Cancer Insti-
tute Common Toxicity Criteria version 3.0. DlTs were 
defined as clinically relevant adverse events (aes; mainly 
Grade 3 or 4) or abnormal laboratory values, occurring 
within 28 days following the first dose of aUY922 in Cycle 
1. Tumor response was assessed by computed tomogra-
phy or magnetic resonance imaging, and using response 
evaluation Criteria in Solid Tumors version 1.0 for efficacy 
evaluations.
Based on reports of Grade 1–3 visual symptoms after 
weekly administration of aUY922 at dose levels of 
≥40 mg/m2 in the CaUY922a2101 study, standard oph-
thalmological assessments were implemented at baseline, 
at the time of reported visual symptom(s) (if any) and at the 
end of treatment.
Pharmacokinetic analysis
Validated liquid chromatography-tandem mass spectrom-
etry assay was used for PK assessments of aUY922 and its 
glucuronide metabolite BJP762. PK assessments were car-
ried out on blood samples obtained pre-infusion and at 5, 
15, and 30 min and 1 h during infusion, followed by 5 and 
30 min and 1, 2, 4, 5, 8, 24, 48 and 72-h post-infusion on 
Cycle 1 Day 1 and Cycle 2 Day 1. a non-compartmental 
analytical method was used to calculate PK parameters of 
maximum observed concentration (Cmax), time at which 
Cmax occurred (Tmax), terminal half-life (T1/2), and area 
under the curve (aUC), for aUY922 and BJP762 in blood, 
utilizing Winnonlin Pro version 5.2.
Results
Patient characteristics and treatment
a total of 31 patients were treated in seven dose cohorts (8, 
16, 22, 28, 40, 54 and 70 mg/m2) between november 2008 
and July 2011 (Table 1). Median duration of drug exposure 
was 7.3 weeks (range 0.1–58.1 weeks) and 55 % of patients 
underwent 1 or 2 treatment cycles [7 patients (23 %) and 
10 patients (32 %), respectively]. The median relative dose 
intensity was 1.0 (range 0.7–1.0). at the time of data cut-
off (5 July 2011), two patients were still receiving treat-
ment on the study. The remaining 29 patients discontinued 
Table 1  Patient demographics, and baseline disease characteristics
ECOG PS eastern Cooperative Oncology Group performance status
Characteristic aUY922 dose (mg/m2)
8 (n = 3) 16 (n = 3) 22 (n = 3) 28 (n = 5) 40 (n = 3) 54 (n = 6) 70 (n = 8) Total, n (%) (N = 31)
Mean age, years 51.3 61.7 52.7 53.6 62.0 62.3 59.4 58.1
Gender, n
 Male 2 1 3 2 1 2 4 15 (48)
eCOG PS, n
 0 2 3 2 3 3 4 4 21 (68)
 1 1 0 1 2 0 2 4 10 (32)
Stage (current), n
 IV 3 3 3 3 3 6 8 29 (94)
 IVa 0 0 0 1 0 0 0 1 (3)
 IVb 0 0 0 1 0 0 0 1 (3)
Tumor type, n
 rectum 0 10 2 0 0 2 5 10 (32)
 Colon 1 1 1 0 1 2 1 7 (23)
 Breast 0 0 0 2 1 1 1 5 (16)
 Head and neck 1 0 0 0 1 0 0 2 (7)
 Pancreas 0 0 0 1 0 0 1 2 (7)
 Stomach 1 1 0 0 0 0 0 2 (7)
 eesophagus 0 0 0 1 0 0 0 1 (3)
 Gall bladder ducts 0 0 0 1 0 0 0 1 (3)
 Other 0 0 0 0 0 1 0 1 (3)
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the study treatment, mainly due to disease progression (27 
patients), and two patients discontinued as a result of aes 
related to study drug (one patient each in the 54 and 70-mg/
m2 cohorts).
Safety and tolerability
The most common aes, regardless of relationship to study 
drug, were diarrhea (65 %), night blindness (42 %), nausea 
and fatigue (both 29 %). Mild-to-moderate diarrhea (65 %), 
night blindness (42 %) and nausea (23 %) were the most 
commonly reported aes possibly related to aUY922 treat-
ment across all doses (Table 2). Visual toxicities, includ-
ing night blindness, photopsia, cataract, eye disorder, optic 
neuritis and blurred vision were observed at dose levels of 
22–70 mg/m2; all were Grade 1 or 2. no patients discontin-
ued aUY922 treatment due to the visual toxicities, which 
were reversible upon discontinuation of treatment. none 
of the visual aes were reported as DlTs. Fifteen patients 
(48 %) experienced aes requiring dose modification or 
interruption. Of these, night blindness (six patients) and eye 
disorder (two patients) were reported. eight patients (26 %) 
experienced serious aes (Saes) and Saes considered to be 
related to the study drug were reported in two patients. One 
patient died during the study as a result of disease progres-
sion, which was considered to be unrelated to study drug.
The dose-determining set (DDS) consisted of (1) all 
patients who received at least three doses of aUY922 within 
the first cycle, were observed for ≥28 days following the 
first dose, and completed all safety evaluations in Cycle 1, 
or (2) any patient who had a DlT within Cycle 1. The DDS 
was used for the BlrM analyses in the determination of 
MTD. among these patients (n = 28), one patient (3.6 %) 
in the 54-mg/m2 cohort experienced DlTs; two aes (Grade 
3 fatigue and Grade 3 decreased appetite) were considered 
to be DlTs and both resolved to Grade 1 within 8 days. Two 
patients who received the 70 mg/m2 dose required repeated 
dose interruption due to visual adverse events, and both 
patients ultimately received a dose reduction to 54 mg/m2. 
although the BlrM would have permitted dose escalation 
beyond 70 mg/m2, a decision to stop further dose escala-
tion was taken based on an assessment by investigators of 
the potential risk of visual toxicities. Visual toxicities at 
the higher doses (22 mg/m2 and above) among those tested 
Table 2  Most common adverse events (≥10 % and Grade 3/4) potentially related to aUY922 treatment
Patients who experienced more than one occurrence of the same event are only counted once within each category
a
 By preferred term
adverse event, na Grade aUY922 dose (mg/m2)
8 (n = 3) 16 (n = 3) 22 (n = 3) 28 (n = 5) 40 (n = 3) 54 (n = 6) 70 (n = 8) Total, n (%) (N = 31)
Diarrhea all 0 0 2 4 2 5 7 20 (65)
3/4 0 0 0 0 0 1 0 1 (3)
night blindness all 0 0 2 2 1 5 3 13 (42)
3/4 0 0 0 0 0 0 0 0
nausea all 0 0 0 0 2 2 3 7 (23)
3/4 0 0 0 0 0 0 0 0
Decreased appetite all 0 1 1 0 0 1 3 6 (19)
3/4 0 0 0 0 0 1 0 1 (3)
Fatigue all 0 0 0 2 0 3 1 6 (19)
3/4 0 0 0 0 0 1 0 1 (3)
rash all 0 2 0 1 0 2 1 6 (19)
3/4 0 0 0 0 0 0 0 0
Vomiting all 0 0 0 0 1 1 3 5 (16)
3/4 0 0 0 0 0 0 0 0
Headache all 0 0 0 0 0 0 3 3 (10)
3/4 0 0 0 0 0 0 0 0
lymphopenia all 0 0 0 2 0 1 0 3 (10)
3/4 0 0 0 0 0 0 0 0
Photopsia all 0 0 1 1 0 0 1 3 (10)
3/4 0 0 0 0 0 0 0 0
Pruritis all 0 1 0 0 0 1 1 3 (10)
3/4 0 0 0 0 0 0 0 0
633Cancer Chemother Pharmacol (2014) 74:629–636 
1 3
were observed, most commonly night blindness and pho-
topsia, although these were only Grade 1 or 2. as a result, 
the MTD was not determined, and the rP2D was, therefore, 
declared as 70 mg/m2 once-weekly IV over 1 h.
Pharmacokinetics
aUY922 reached peak concentrations in blood around the 
end of the infusion. Following the initial rapid decline in 
concentration levels after the IV administration was com-
pleted, blood aUY922 concentration declined slowly, with 
a mean T1/2 of 127 h at 70 mg/m2 (Table 3; Fig. 1). The T1/2 
was prolonged with increasing dose (64 h at 8 mg/m2 to 
127 h at 70 mg/m2). Cmax for both aUY922 and the metabo-
lite BJP762 generally increased in a dose-proportional man-
ner over the entire dose range. aUClast of aUY922 increased 
with dose (from 8 to 28 mg/m2), but was saturated at higher 
dose levels (Fig. 2; Tables 3, 4). Due to limited sampling 
time points, the plasma concentration–time profile could 
not be fully characterized; Cmax and aUC for aUY922 in 
plasma had a tendency to increase in a dose-proportional 
manner even at the higher dose levels (40–70 mg/m2). 
Table 3  Summary of PK 
parameters (mean ± SD, unless 
otherwise stated) at Cycle 1 
Day 1 for blood aUY922 [28–
70 mg/m2 (four highest doses)]
PK pharmacokinetics, SD 
standard deviation
a
 Data missing for one patient
aUY922 PK parameter aUY922 dose (mg/m2)
28 (n = 5) 40 (n = 3) 54 (n = 6) 70 (n = 8)
Tmax [median, h (range)] 0.50 (0.48–1.07) 1.05 (0.50–1.05) 0.76 (0.48–1.17) 1.02 (0.23–1.17)
Cmax (ng/ml) 457 ± 101 710 ± 42 1,050 ± 118 1,100 ± 118
aUC(0–last) (h·ng/ml) 6,810 ± 1,090 6,960 ± 1,270 8,880 ± 1,710 8,540 ± 895
aUC(0–inf) (h·ng/ml) 9,550 ± 2,460 11,400 ± 3470a 12,300 ± 2720a 12,600 ± 1,720
Cl (l/h) 4.79 ± 1.68 5.74 ± 1.16a 7.24 ± 1.97a 8.60 ± 1.30
Vz (l) 646 ± 111 980 ± 132a 1,190 ± 151a 1,570 ± 293
T1/2 (h) 98.7 ± 23.0 123.0 ± 40.8a 120.0 ± 28.5a 127.0 ± 18.8
Fig. 1  Mean aUY922 concen-
tration–time profiles in blood on 
Cycle 1 Day 1
Fig. 2  relationship between 
aUY922 dose and blood phar-
macokinetics parameters
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Blood PK profiles for aUY922 on Day 1 of Cycle 2 were 
similar to those on Day 1 of Cycle 1. The geometric mean 
of accumulation ratios for Cmax (Day 1 of Cycle 1 to Day 1 
of Cycle 2) ranged from 1.01 to 1.28. The ratios for aUClast 
(Day 1 of Cycle 1 to Day 1 of Cycle 2) ranged between 
0.992 and 1.60. Hence, there was no significant drug accu-
mulation with once-weekly IV doses of aUY922.
efficacy
One patient (rectal carcinoid tumor with lung metastatic 
lesions) achieved a confirmed partial response (Pr) for a 
duration of >7 months (Table 5; Fig. 3). Ten patients (32 %) 
achieved a best overall response of stable disease (SD) 
lasting ≥8 weeks, including five out of the eight patients 
(63 %) in the 70-mg/m2 cohort; no patients achieved a com-
plete response. The disease control rate (DCr; Pr + SD) 
across all dose levels was 36 % (Table 5).
Discussion
There are a number of HSP90 inhibitors under clinical 
development, both as single agents and in combination with 
other agents [19, 20]. Hepatotoxicity has been reported in 
both the early and late stages of development of geldana-
mycin-based HSP90 inhibitors [21, 22]. In this study in 
Japanese patients with advanced solid tumors, single-agent 
aUY922 demonstrated an acceptable safety profile at dose 
levels of 8–70 mg/m2 with potential clinical activity (DCr 
36 %). The MTD was not established, and although the 
BlrM would have permitted further dose escalation, a 
decision was made not to escalate the dose any further than 
the well-tolerated dose of 70 mg/m2 based on the potential 
risk of visual toxicity, the symptoms of which were simi-
lar to those reported in the preceding global phase I study 
(CaUY922a2101), and the rP2D was thus declared as 
70 mg/m2once-weekly.
Hepatotoxicity was not reported as a frequent ae sus-
pected to be related to study drug, or as a DlT; the most 
common aes suspected to be related to this study drug 
included Grade 1 or 2 diarrhea (65 %), night blindness 
(42 %) and nausea (23 %). Only Grade 1 or 2 visual aes 
(most commonly night blindness and photopsia) were 
reported at the 22–70 mg/m2 dose levels. Similar safety 
findings were observed in the preceding global Phase I 
CaUY922a2101 study [14]. Visual disturbances have been 
reported with other geldanamycin and non-geldanamycin 
Table 4  Summary of PK parameters (mean ± SD, unless otherwise stated) at Cycle 1 Day 1 for blood BJP762 [28–70 mg/m2 (four highest 
doses of aUY922)]
PK pharmacokinetics, SD standard deviation
a
 Data missing for one patient
b
 Data missing for two patients
BJP762 PK parameter aUY922 dose (mg/m2)
28 (n = 5) 40 (n = 3) 54 (n = 6) 70 (n = 8)
Tmax [median, h (range)] 1.07 (1.05–1.17) 1.05 (1.05–1.07) 1.08 (1.02–1.22) 1.13 (1.00–1.23)
Cmax (ng/ml) 611 ± 201 964 ± 775 1,060 ± 569 1,330 ± 904
aUC(0–last) (h·ng/ml) 3,700 ± 2,170 5,690 ± 5,250 6,320 ± 4,650 5,530 ± 3,320
aUC(0–inf) (h·ng/ml) 3,940 ± 2,320 5,830 ± 5,300 6,770 ± 5200a 5,020 ± 3340b
T1/2 (h) 59.1 ± 28.8 33.1 ± 12.1 49.1 ± 24.0a 46.5 ± 27.9b
Table 5  Best overall response (response evaluation Criteria in Solid Tumors)
response, n aUY922 dose (mg/m2)
8 (n = 3) 16 (n = 3) 22 (n = 3) 28 (n = 5) 40 (n = 3) 54 (n = 6) 70 (n = 8) Total, n (%) (N = 31)
Complete response 0 0 0 0 0 0 0 0
Partial response 0 0 0 0 0 1 0 1 (3)
Stable disease 1 1 0 1 1 1 5 10 (32)
Progressive disease 2 2 3 4 2 3 3 19 (61)
Unknown 0 0 0 0 0 1 0 1 (3)
Overall response rate (Cr + Pr) 0 0 0 0 0 1 0 1 (3)
Disease control rate  
(Cr + Pr + SD)
1 1 0 1 1 2 5 11 (36)
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HSP90 inhibitors [23–25]. These visual aes are regarded 
as class adverse effects, which are possibly related to tis-
sue distribution of water-soluble agents facilitating a high 
retina:plasma concentration ratio, as well as the retinal 
elimination profile [26]. The safety profile of aUY922 was 
similar to that reported in the preceding CaUY922a2101 
study [14], and ongoing Phase II studies [15, 16]. Cmax 
for aUY922 in blood increased generally in a dose-pro-
portional manner over the entire dose range. Blood PK 
parameters of aUY922 in Japanese patients were also com-
parable to those observed in non-Japanese patients in the 
CaUY922a2101 study [14]. aUC for aUY922 in blood 
increased with dose at lower doses, but was saturated at 
higher doses. This less than dose-proportional increase in 
blood aUY922 is likely caused by a concentration-depend-
ent and saturable blood cell partition of aUY922. There 
was no significant drug accumulation following once-
weekly intravenous infusion of aUY922.
In summary, aUY922 has shown an acceptable safety 
profile and demonstrated promising clinical activity in Jap-
anese patients, with one patient achieving a confirmed pro-
longed Pr, and several patients achieving long duration SD 
at higher dose levels.
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